Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Meisel

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Clinical Breast Cancer|July 16, 2020
The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without RadiotherapyChase E Escott, David Zaenger, Jeffrey M Switchencko, et al.
Acta Tropica|December 16, 2018
IgG reactivity with 40-35 kDa soluble and membrane antigen of Strongyloides venezuelensis in immunocompromised patientsMarcelo Andreetta Corral, Fabiana Martins de Paula, Dirce Mary C L Meisel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancerJ L Meisel, D M Hyman, K Garg, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Molecular and Biochemical Parasitology|December 28, 2019
Shotgun proteomics of Strongyloides venezuelensis infective third stage larvae: Insights into host-parasite interaction and novel targets for diagnosticsPriscilla D M Fonseca, Marcelo A Corral, Miguel Cosenza-Contreras, et al.
Clinics (Sao Paulo, Brazil)|June 13, 2019
Screening of Strongyloides infection using an ELISA test in transplant candidatesBeatriz Toledo, Marcelo A Corral, Dirce Mary C L Meisel, et al.
Breast Cancer Research : BCR|September 4, 2019
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)Tejal A Patel, Joe E Ensor, Sarah L Creamer, et al.
ESMO Open|January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)E Agostinetto, G Pfeiler, D Hlauschek, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Clinical Breast Cancer|July 16, 2020
The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without RadiotherapyChase E Escott, David Zaenger, Jeffrey M Switchencko, et al.
Acta Tropica|December 16, 2018
IgG reactivity with 40-35 kDa soluble and membrane antigen of Strongyloides venezuelensis in immunocompromised patientsMarcelo Andreetta Corral, Fabiana Martins de Paula, Dirce Mary C L Meisel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancerJ L Meisel, D M Hyman, K Garg, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Molecular and Biochemical Parasitology|December 28, 2019
Shotgun proteomics of Strongyloides venezuelensis infective third stage larvae: Insights into host-parasite interaction and novel targets for diagnosticsPriscilla D M Fonseca, Marcelo A Corral, Miguel Cosenza-Contreras, et al.
Clinics (Sao Paulo, Brazil)|June 13, 2019
Screening of Strongyloides infection using an ELISA test in transplant candidatesBeatriz Toledo, Marcelo A Corral, Dirce Mary C L Meisel, et al.
Breast Cancer Research : BCR|September 4, 2019
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)Tejal A Patel, Joe E Ensor, Sarah L Creamer, et al.
ESMO Open|January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)E Agostinetto, G Pfeiler, D Hlauschek, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Pageof 15